SCHEMBL659860

SCHEMBL659860

Cc1nc2ccncn2c1-c1ccnc(C2(c3cccc(C(=O)Nc4ccccc4N)c3)CC2)n1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 16/20 0.51
CCNE1 P24864 3/20 0.39
CDK2 P24941 3/20 0.39
CDK4 P11802 2/20 0.39
IGF1R P08069 1/20 0.38
HDAC2 Q92769 3/20 0.37
HDAC3 O15379 2/20 0.36
HDAC4 P56524 2/20 0.36
HDAC7 Q8WUI4 2/20 0.36
HDAC10 Q969S8 2/20 0.36
HDAC11 Q96DB2 2/20 0.36
HDAC8 Q9BY41 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC9 Q9UKV0 2/20 0.36
HDAC5 Q9UQL6 2/20 0.36
ABL1 P00519 1/20 0.36
PDGFRB P09619 1/20 0.36
KDR P35968 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3349942 0.91 HDAC1 (0.62) HDAC1CCNE1CDK2CDK4IGF1R
SCHEMBL658310 0.87 CDK2 (0.37) HDAC1CCNE1CDK2CDK4HDAC2
SCHEMBL658533 0.82 HDAC1 (0.67) HDAC1CCNE1CDK2CDK4IGF1R
SCHEMBL655749 0.81 HDAC1 (0.50) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL657016 0.80 HDAC1 (0.49) HDAC1CCNE1CDK2CDK4HDAC2
SCHEMBL656821 0.80 HDAC1 (0.49) HDAC1
SCHEMBL655630 0.79 HDAC1 (0.68) HDAC1CCNE1CDK2CDK4
SCHEMBL3353564 0.79 HDAC1 (0.56) HDAC1CCNE1CDK2CDK4
SCHEMBL657139 0.79 HDAC1 (0.54) HDAC1CCNE1CDK2CDK4
SCHEMBL3357662 0.78 CDK2 (0.50) HDAC1CCNE1CDK2CDK4IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-02-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 HDAC1 1/4885CCNE1 1992/4885CDK2 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.